Oppenheimer & Co. Inc. Purchases 80 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oppenheimer & Co. Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,339 shares of the biopharmaceutical company’s stock after purchasing an additional 80 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $10,867,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on REGN shares. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 9th. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. Finally, StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,153.35 on Friday. The company has a market capitalization of $127.15 billion, a PE ratio of 34.07, a price-to-earnings-growth ratio of 3.89 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a 50-day simple moving average of $1,124.22 and a 200 day simple moving average of $1,025.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business posted $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock valued at $11,498,705 over the last ninety days. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.